To confirm that Lucica ® Glycated Albumin-L is useful for the intermediate term (preceding 2-3 weeks) monitoring of glycemic control in patients with diabetes.
In order to confirm that Lucica ® Glycated Albumin-L is useful for the intermediate term (preceding 2-3 weeks) monitoring of glycemic control in patients with diabetes, subjects with Type 1 or Type 2 diabetes will be enrolled whose HbA1c values range from 7.5% to 12% (or higher) in Group 1 and \<7.5% in Group 2 at Visit 1, and the comparison of glycated albumin (GA) and other glycemic control indices will be performed during 6 months in 8 clinical sites in US. Group 1 will consist of 90 evaluable subjects who have a change in diabetes management to improve glycemic control; this therapy can include oral agents, insulin, or noninsulin injectable anti-diabetic medications. Group 2 will consist of 40 evaluable subjects already on a stable diabetic management program, who have had no change in treatment in the last 3 months and for whom there is no plan to make a change during the study period.
Study Type
OBSERVATIONAL
Enrollment
150
National Research Institute - Huntington Park
Los Angeles, California, United States
National Research Institute-Westlake
Los Angeles, California, United States
Kentucky Diabetes Endocrinology Center
Lexington, Kentucky, United States
Tulane University
New Orleans, Louisiana, United States
Compare the Pearson Correlation of Glycated Albumin (GA) and Fructosamine Within All Subjects With the Performance Goal of 0.8
Time frame: From baseline to 6 months
Spearman Correlation Analysis of Changes in GA, HbA1c, and 7-day Interval Mean Blood Glucaose (MBG) in the First 3 Months in Group 1
Comparing the Spearman correlation of changes in GA and MBG to the Spearman correlation of changes in HbA1c and MBG, from baseline to any matching post-baseline visit in the first 3 months in Group 1.
Time frame: From baseline to the first 3 months after enrollment in Group 1
Kendall Correlation Analysis of Changes in GA, HbA1c, and 7-day Interval MBG in the First 3 Months in Group 1
Comparing the Kendall correlation of changes in GA and MBG to the Kendall correlation of changes in HbA1c and MBG, from baseline to any matching post-baseline visit in the first 3 months in Group 1.
Time frame: From baseline to the first 3 months after enrollment in Group 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Nebraska Medical Center
Omaha, Nebraska, United States
Texas Diabetes & Endocrinology, P.A. -Austin
Austin, Texas, United States
Dallas Diabetes and Endocrine Center
Dallas, Texas, United States
Capital Clinical Research Center
Olympia, Washington, United States